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Abstract
Systemic Sclerosis (SSc) is a rare fibrotic autoimmune disorder for which no cura-
tive treatments currently exist. Metabolic remodelling has recently been implicated 
in other autoimmune diseases; however, its potential role in SSc has received little 
attention. Here, we aimed to determine whether changes to glycolysis and glutami-
nolysis are important features of skin fibrosis. TGF-β1, the quintessential pro-fibrotic 
stimulus, was used to activate fibrotic pathways in NHDFs in vitro. Dermal fibro-
blasts derived from lesions of SSc patients were also used for in vitro experiments. 
Parameters of glycolytic function were assessed using by measuring extracellular 
acidification in response to glycolytic activators/inhibitors, whilst markers of fibrosis 
were measured by Western blotting following the use of the glycolysis inhibitors 
2-dg and 3PO and the glutaminolysis inhibitor G968. Succinate was also measured 
after TGF-β1 stimulation. Itaconate was added to SSc fibroblasts and collagen exam-
ined. TGF-β1 up-regulates glycolysis in dermal fibroblasts, and inhibition of glycolysis 
attenuates its pro-fibrotic effects. Furthermore, inhibition of glutamine metabolism 
also reverses TGF-β1-induced fibrosis, whilst glutaminase expression is up-regulated 
in dermal fibroblasts derived from SSc patient skin lesions, suggesting that enhanced 
glutamine metabolism is another aspect of the pro-fibrotic metabolic phenotype in 
skin fibrosis. TGF-β1 was also able to enhance succinate production, with increased 
succinate shown to be associated with increased collagen expression. Incubation of 
SSc cells with itaconate, an important metabolite, reduced collagen expression. TGF-
β1 activation of glycolysis is a key feature of the fibrotic phenotype induced by TGF-
B1 in skin cells, whilst increased glutaminolysis is also evident in SSc fibroblasts.
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1  | INTRODUC TION
Systemic Sclerosis (SSc) is characterized by dysregulated fibro-
blast to myofibroblast differentiation and excessive extracellular 
matrix deposition, resulting in skin fibrosis.1 The disease contains 
two subtypes: ‘limited’ (lSSc) and ‘diffuse’ (dSSc). The prognosis is 
significantly better for lSSc, with symptoms limited to skin thick-
ening in discrete areas; however, for dSSc the skin symptoms are 
more severe and widespread, with fibrosis also occurring in in-
ternal organs which results in mortality.2 Although treatment for 
managing individual symptoms has improved, a pressing need for 
therapeutics that can significantly slow or even reverse the dis-
ease persists.3
Following the discovery of ‘the Warburg effect’,4 it is become 
well established that drastic alterations of the metabolic profile are 
a key feature of the majority of cancers. Although the enhanced gly-
colysis ubiquitous in cancer is well characterized, whether this oc-
curs at the expense of the much more efficient energy producing 
OXPHOS pathway is controversial.5,6 One hypothesis for this seem-
ingly counter-intuitive metabolic remodelling is glycolysis’ additional 
role in generating biosynthetic intermediates which support protein 
synthesis and cellular proliferation. Given that SSc is a disease in 
which myofibroblast proliferation and ECM synthesis are key, we 
sought to investigate whether metabolic changes are present and 
relevant to the pathogenesis. Recently, changes to the glycolytic 
phenotype have been identified in a number of other autoimmune7-9 
and fibrotic disorders,10,11 including TGF-β-mediated GLUT1 up-reg-
ulation12—however, this is the first time metabolic reprogramming 
has been characterized in SSc.
In addition to glycolysis, glutamine metabolism is known to 
become significantly altered in cancer13-15 and is also becoming 
increasingly recognized as a potential mediator of pathogenicity in 
autoimmune16,17 and fibrotic disorders.18 Glutamine metabolism is 
also similar to glycolysis in that it produces a number of substrates 
for biosynthetic pathways, thus supporting proliferation and pro-
tein synthesis. Particularly important in the context of fibrosis 
is the production of α-ketoglutarate, an essential substituent of 
collagen I—the most abundantly expressed ECM component in 
fibrosis.
TGF-β1 is a renowned activator of fibrotic genes and has been 
heavily implicated in the pathogenesis of SSc,17 making it a useful tool 
to model skin fibrosis in vitro. Using TGF-β1 treated normal healthy 
dermal fibroblasts (NHDFs) and fibroblasts derived from SSc patient 
skin lesions, we show that TGF-β1 enhances glycolytic parameters 
and that inhibition of both glycolysis and glutamine metabolism at-
tenuates the expression of pro-fibrotic markers. Furthermore, SSc 
patient-derived fibroblasts with enhanced collagen I expression also 
displayed enhanced glycolysis, whilst glutaminase was up-regulated 
in all SSc fibroblasts, regardless of enhanced collagen I. This frames 
glycolysis and glutamine metabolism as potentially key mediators 
of fibrosis in SSc that can be targeted therapeutically. We further 
demonstrate the pro-fibrotic role of succinate and that the active 
metabolite itaconate reduced collagen in SSc fibroblasts.
2  | MATERIAL S AND METHODS
2.1 | Ethics
Full ethical approval was given for this work by the Northumbria 
University ethics committee and the research ethics committee 
Sunderland under REC/13/NE/0089 and followed the declaration 
of Helsinki guidelines and full informed consent. Four SSc patients 
were included in the study. All four SSc patients were defined as 
early diffuse (2 years or less from first non-Raynaud's symptom), and 
all patients were female mean age 54 years and positive for antibod-
ies to scl-70.
All SSc patients are on no treatment at all (treatment naïve pa-
tients). Healthy controls were derived from female donors undergo-
ing adipose reduction surgery. In both patients and controls, a 5-mm 
punch biopsy was taken from the affected area and dermal fibro-
blasts isolated from the biopsy by enzymatic digestion using dispase 
and used at passages 1-10.
2.2 | Reagents
All reagents used were purchased from Sigma-Aldrich unless other-
wise stated.
2.3 | Cell culture
Dermal fibroblasts derived from early diffuse SSc patient lesions 
(n = 4) or healthy controls (n = 3) were grown in Dulbecco's Modified 
Eagle's Medium (DMEM, Gibco) supplemented with 10% foetal bo-
vine serum (FBS, Gibco), 1% penicillin/streptomycin (Gibco), and 
2 mmol/L L-glutamine (Gibco) and kept at a temperature of 37°C 
in an atmosphere of 5% CO2. For TGF-β1 experiments, cells were 
serum starved overnight prior to treatment with 10 ng/mL TGF-β1 
(ab50036, Abcam) for 48 hours in fresh media containing 0.1% FBS.
The inhibitors 2-DG, 3PO and G968 (Sigma) were dissolved in 
dH2O (2-DG) or DMSO (3PO and G968) and added at concentra-
tions of 10 mmol/L, 8 and 10 µmol/L, respectively. DMSO concen-
trations were kept at 0.1% or below and constant for all wells. Cell 
viability for these doses was tested using trypan blue to ensure 
against cell toxicity. The concentration of the inhibitors was in-
formed by the literature and verified by viability assays using ala-
mar blue (Figure S1), whereby only doses at which no toxic effect 
occurred were chosen.
2.4 | Western Blotting
After washing twice with 1× PBS, cells were lysed on ice using 1× 
RIPA buffer (10 mmol/L tris-Cl pH 8.0, 0.1% sodium deoxycholate, 
0.1% SDS, 1% Triton X-100, 140 mmol/L NaCl) containing protease 
inhibitors. Protein lysates were denatured in laemmli buffer and then 
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separated on a 10% SDS-PAGE gel before being transferred onto a 
nitrocellulose membrane (Bio-Rad). Immunoblotting was performed 
using the following primary antibodies diluted in 5% milk block: 
α-tubulin (ab7291, Abcam), collagen I (ab138492, Abcam), hexoki-
nase II (ab104836, Abcam), α-SMA (Abcam, ab7817, Abcam), KGA/
GAC (12855-1-AP, Proteintech). The secondary antibodies used 
were goat anti-rabbit HRP (P0448, Dako) and rabbit anti-mouse 
HRP (PO260, Dako), and the blot was developed using SuperSignal™ 
West Dura Extended Duration Substrate ECL detection reagent 
(Thermo), with the chemiluminescent signal exposed on a gel dock 
system (Syngene).
2.5 | Metabolic assays
Glycolysis, glycolytic flux and glycolytic capacity were meas-
ured using a Seahorse XFp Analyser. On the day of the assay, cells 
were switched to Seahorse XF Base DMEM pH 7.4 (Agilent) sup-
plemented with 2 mmol/L glutamine and any TGF-β1 or treatment 
compounds in the media previously. The glycolytic parameters were 
then deduced by measuring the ECAR (extracellular acidification 
rate) in response to the sequential addition to the wells of glucose 
(10 mmol/L), oligomycin (1 µmol/L) and 2-DG (50 mmol/L) (all Sigma). 
Oxidative phosphorylation was also assessed using the Seahorse 
Analyser by measuring the OCR (oxygen consumption rate) in cells 
incubated in Seahorse XF Base DMEM with 2 mmol/L glutamine- 
which is determined by the Seahorse analyser in real time in pmol/
min of the media that surrounds the cells. This is then normalized by 
taking account of total protein (µg), and data are shown relative to 
control untreated as a percentage.
2.6 | qRT-PCR
SSc and HC dermal fibroblasts were isolated and cultured in DMEM 
as described above. RNA was isolated using Trizol (Invitrogen) 
and 1 µg of RNA was reverse transcribed using Superscript RT 
(Invitrogen). qPCR was performed using 2 µL cDNA with primers 
for Hexokinase 2 (HK2) for 5′ TTCTTGTCTCAG ATTGAGAGTGAC 
3′, HK2 rev 5′ TTGCAGGATGGCTCGGACTTG 3′; GLUT1 for 5′ 
CTTCCAGTATGTGGAGCAACTGT, GLUT1 rev 5′ GCACAGTG 
AAGATGATGAAGACG 3′, PFKFB3 for 5′ ACCAAAGATCACCCACGG 
ATGT 3′, PFKFB3 rev 5′ AGCGAGTGCAGAATGGACACAA 3′ and 
18S: for 5′-GAATGGCTCATTAAATCAGTTATGG-3′, rev 5′-TATT 
AGCTCTAGAATTACCACAGTTATCC-3’ using SYBR green (Sigma). 
Data were normalized to the housekeeping gene 18S and relative 
expression quantified using the delta-delta Ct method from four 
independent donors. All samples were run in triplicate and sam-
ples lacking RT were run as negative controls to confirm target 
amplification.
Fibroblasts were cultured with or without TGF-β1 alone 
or pre-treated for 1 hour with the Smad inhibitor SB431542 
(Sigma) 1 µmol/L or DMSO vehicle control (0.1% v/v) and 
stimulated for 48 hours in culture. After 48 hours RNA was 
harvested and qPCR was performed with specific prim-
ers for GLS-1 for 5’-CTGGAAGCCTGCAAAGTAAAC-3’, Rev 
5’-TGAGGTGTGTACTGGACTTGG-3’. Data are normalized to 18S 
and shown as fold change compared to control. Fibroblasts were 
culture with SB431542 (Sigma) at 1 µmol/L or DMSO vehicle con-
trol (0.1% vol/vol) and then all cultures treated with TGF-β1 (10 ng/
mL) for a further 36 hours and then RNA isolated by Trizol and qRT-
PCR performed for collagen1A1 as previously described.19 Also 
cells were incubated with the Fibroblast Growth Factor Receptor 3 
(FGFR3) inhibitor PD173074 (Sigma, UK) 20 nmol/L (dose was cho-
sen based on previous study20) or DMSO vehicle control and then 
all cultures treated with TGF-β1 (10 ng/mL) for a further 36 hours 
and then RNA isolated by Trizol and qRT-PCR performed for Gls1 as 
described above.
2.7 | NAD+ measurements
Following a 48-hour incubation in TGF-β1, cells were trypsinized and 
re-suspended in 1× PBS. The cell suspension was then mixed with a 
0.2 mol/L NaOH 1% DTAB solution before the addition of 0.4 mol/L 
HCl, and then incubated at 60°C for 15 minutes to lyse the cells 
under conditions in which NAD+ is stable and NADH is degraded. 
NAD+ levels were then quantified using a commercially available lu-
minescent cycling assay (G9071, Promega) as detailed in the manu-
facturer instructions.
2.8 | Succinate quantification
NHDFs were cultured with or without TGF-β1 (10 ng/mL) for 
36 hours after which time the cells were removed and succinate 
was quantified according to manufacturer's instructions colori-
metrically (Abcam). Four individual donors were used and all ran 
in triplicate.
2.9 | Succinate treatment
NHDFs were cultured in 6-well plates and then treated with suc-
cinate (5 mmol/L- Sigma) or untreated in low FBS DMEM and after 
48 hours the RNA was extracted and qPCR was performed for col-
lagen1A1 and 18S. Data were normalized to 18S and was from 4 
independent cultures. Primers for collagen1A1 forward 5′-CAA GAG 
GAA GGC CAA GTC GAG G-3′, reverse 5′- CGT TGT CGC AGA CGC 
AGA T-3’. All samples were run in triplicate and samples lacking RT 
served as negative controls.
In other experiments, cells were treated with succinate 
(5 mmol/L) or untreated and after 15 minutes stimulation cells were 
lysed in RIPA buffer containing a cocktail of protease and phospha-
tase inhibitors (Thermo Fisher). The lysate was subjected to PAGE, 
and Western blotting was performed using phosphorylated P38 
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MAPK thy180-ty182 residues 1:600 dilution (Cell signaling technol-
ogy) and was reprobed with beta-actin 1:20,000 dilution (Abcam).
2.10 | Smad-binding element reporter assay
SBE luciferase reporter that contains four copies of the Smad-
binding element was used and 500 ng was transfected into NDHFs 
using Lipofectamine 3000 (Thermo Fisher) in six-well plates with 
Renilla used to normalize transfection efficacy. After 24 hours post-
transfection Succinate or nothing was added to the cells (5 mmol/L) 
and after a further 24 hours cells were lysed and luciferase was 
measured using a luminometer. All samples were run in duplicate and 
three independent samples were used in this experiment.
2.11 | 4-Octyl Itaconate treatment
SSc dermal fibroblasts were cultures in 6-well plates from three 
separate donors and treated with the cell permeable derivative of 
itaconate 4-octyl itaconate (Sigma) at 100 µmol/L or DMSO as this 
is the vehicle. This concentration was chosen as this appeared to be 
effective in inhibiting IL-1β and IL-6 release in macrophages.21 After 
48 hours the cells were lysed and subjected to Western blotting for 
collagen 1 as described above. The blot was reprobed for β-actin 
(Abcam,UK) to confirm equal loading of total protein.
4-octyl itaconate was administered to SSc fibroblasts or 
DMSO and after 24 hours RNA was harvested from the cells using 
Trizol and RT-qPCR was performed for the nuclear factor eryth-
roid 2-related factor (nrf-2) target gene HO-1 with specific prim-
ers HO-1 For 5’-TATCGTGCTCGCAATGAACACTCTG -’ Rev 
5’-GTTGAGCAGGAAGGCGGTCTTAG-3’ and 18S: for 5′-GAATGGCT 
CATTAAATCAGTTATGG-3′, rev 5′-TATTAGCTCTAGAATTACCACAG 
TTATCC-3’ using SYBR green (Sigma, UK). Data were normalized to 
the housekeeping gene 18S and relative expression quantified using 
the delta-delta Ct method. All samples were run in triplicate and 
samples lacking RT were run as negative controls to confirm target 
amplification.
2.12 | Statistical analysis
Data for the NAD+ assays are presented as the mean ± standard 
error of the mean (SEM) and a Student's t test was used to test for 
significance between the TGF-β1 treated and untreated NHDFs. 
For the analysis of OXPHOS/glycolytic parameters, OCR/ECAR 
is expressed as the mean percentage of the control mean. A t test 
was used for the OXPHOS assay, whereas significance was probed 
F I G U R E  1   Glycolysis is a vital component of TGF-β1 induction of fibrotic proteins in NHDFs. A, The glycolytic parameters of NHDFs 
treated with/without 10 ng/mL TGF-β1 were measured on a Seahorse XFp Analyser by performing a glycolysis stress test. B, OXPHOS was 
also measured in NHDFs treated with/without 10 ng/mL TGF-β1, by measuring the oxygen consumption rate (OCR). Data shown are the 
percentage change compared with control untreated cells, and OCR is measured by pmol/min normalized to total protein. C, NHDFs were 
treated with/without 10 ng/mL TGF-β1 and/or the glycolysis inhibitor 2-DG (10 Mm), and the proteins indicated were measured by Western 
blotting. D, Likewise, Western blotting was used to observe changes to proteins of interest in NHDFs were treated with/without 10 ng/
mL TGF-β1 and/or the glycolytic flux inhibitor 3PO (8 µmol/L). *Represents P < .05. Error bars represent the mean (n = 3) ±SEM. Statistical 
significance was tested for using 1-way ANOVA followed by a Bonferroni post hoc test
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using one-way ANOVA for parameters of glycolytic function and a 
Bonferroni post hoc test was performed to test for significance be-
tween all the different treatment conditions. For all other analysis, a 
t test was performed. A value of P < .05 was set as the threshold of 
significance for all analyses performed.
3  | RESULTS
3.1 | TGF-β1 enhances glycolysis in NHDFs
To determine whether the pro-fibrotic stimulus TGF-β1 induces 
metabolic changes in NHDFs, basal OXPHOS and parameters of 
glycolytic function were measured following TGF-β1 treatment. We 
found no notable changes to OXPHOS (Figure 1B), whereas there 
were large changes to glycolysis (Figure 1A), with basal glycolysis 
significantly enhanced (1.26-fold, P = .02). In addition to basal gly-
colysis, the other glycolytic parameters measured were glycolytic 
capacity (glycolysis under conditions in which ATP generation via 
OXPHOS is inhibited, forcing glycolysis to work at maximal capac-
ity) and glycolytic reserve (the difference between basal glycolysis 
and the glycolytic capacity), both of which were also up-regulated 
(glycolytic capacity—1.34-fold, P = .03, glycolytic reserve—1.26 fold, 
P = .04).
The increases in glycolytic capacity and reserve suggest that 
TGF-β1 treated cells are still somewhat dependent on OXPHOS; 
however, they are much better equipped to deal with mitochondrial 
inhibition and quickly up-regulate glycolysis as required. There was 
no significant difference apparent in the OCR in TGF-β1 treated 
cells compared with control (Figure 1B—no significant difference 
between groups).
3.2 | Inhibition of glycolysis attenuates TGF-β1 
induced fibrosis in NHDFs
Although there was up-regulation of glycolysis following TGF-β1 
stimulation, given TGF-β1 is a multi-functional cytokine we sought 
to identify whether enhanced glycolysis was relevant to the pro-fi-
brotic phenotype, using the prototypical glycolytic inhibitor 2-deox-
yglucose (2-DG).22 2-DG potently reduces expression of the fibrotic 
marker collagen I following TGF-β1 treatment (Figure 1C), although 
given 2-DG completely blocks glycolysis this would be an unsuitable 
therapeutic for SSc treatment. However, the glycolytic flux inhibitor 
3PO, which inhibits cellular capacity to quickly up-regulate glyco-
lysis rather than glycolysis per se,23 was also able to attenuate the 
TGF-β1-driven increase in collagen I (Figure 1D) and thus represents 
a feasible alternative to 2-DG in the context of disease treatment.
Given that the conversion of NAD+ to NADH is a key step in 
glycolysis, NAD+ is a limiting factor for glycolytic activity and is 
depleted following TGF-β1 up-regulation of glycolysis (3.2-fold, 
P = .008) (Figure 2A). Because of this dependency on NAD+ availabil-
ity, diminishing the cellular NAD+ reserve by inhibiting nicotinamide 
phosphoribosyltransferase (NAMPT) (the rate-limiting enzyme in 
NAD+ production via the NAD+ salvage pathway) with the specific 
inhibitor FK866 causes a significant decrease in glycolysis (TGF-β1 
vs TGF-β1 + FK866 3.7-fold, P = .0043), glycolytic capacity (TGF-
β1 vs TGF-β1 + FK866 2.74-fold, P = .0005) and glycolytic reserve 
(TGF-β1 vs TGF-β1 + FK866 455-fold, P < .0001) (Figure 2B). This 
also translates to reduced collagen production in TGF-β1 treated 
NHDFs (Figure 2C), once again highlighting the important role of 
glycolysis for the induction of fibrosis in vitro. FK866 is anti-cancer 
agent which can be cytotoxic to cells; hence, prior to these exper-
iments a dose-response curve using alamar blue to assess viability 
was done which identified 10 nmol/L as a non-toxic dose.
3.3 | Inhibition of glutamine metabolism 
antagonises TGF-β1 enhancement of glycolysis and 
fibrosis in NHDFs
Glutamine metabolism, aka glutaminolysis, is another metabolic 
pathway, which plays a key role fuelling cellular growth and thus may 
also contribute to the myofibroblast transition. Glutaminolysis yields 
the key ECM precursor α-ketoglutarate as well as providing nitrogen 
required for pyridine and purine biosynthesis—an important path-
way to facilitate enhanced proliferation.
To test the importance of glutamine to TGF-β1 induced fibrosis, 
varying concentrations of glutamine were added to NHDFs treated 
with or without TGF-β1, and the fibrotic markers collagen I and 
α-SMA were measured (Figure 3A). Other than a surprising increase 
in α-SMA production at 8 mmol/L glutamine for the cells without 
TGF-β1 stimulation, the effect of varying glutamine concentration 
is unremarkable. However, this was contradicted by the suppression 
of collagen expression when TGF-β1 treated cells were co-incubated 
with the specific glutaminase inhibitor G968 (Figure 3B). However, 
the glutaminase inhibitor did not alter the gene expression of colla-
gen1A1 in the presence of TGF-β1 (Figure 3C) control 1.03 (SD 0.05) 
v 0.94 (SD 0.06) P = .131 no significant difference Student's t test 
n = 3. On the whole, this evidence suggests glutamine metabolism is 
important for TGF-β1 mediated fibrosis, with the conflicting results 
from the glutamine titration possibly due to the cellular glutamine 
reserve not being fully depleted after removal of glutamine from the 
media.
3.4 | Glutamine metabolism but not glycolysis is 
ubiquitously up-regulated in SSc fibroblasts
Glycolysis was measured in SSc fibroblasts derived from patient skin 
lesions (n = 4) and compared with healthy controls (n = 3) (Figure 4A). 
There was large variation within the cohort, perhaps reflecting the 
heterogeneous nature of the disease. SSc fibroblasts from only one 
donor showed an increase (non-significant) in glycolysis compared 
with controls, whilst glycolysis was significantly down in another 
patient's fibroblasts. Interestingly, despite missing out on statistical 
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significance the glycolytic reserve was increased in the fibroblasts 
from all patients (1.34-fold average increase) suggesting these cells 
may have an enhanced capacity to become glycolytic under condi-
tions of impaired OXPHOS. It is also noteworthy that collagen I ex-
pression was only up-regulated in the two sets of SSc fibroblasts 
with both the highest glycolytic reserve (increased by 1.38-fold and 
1.57-fold respectively) (Figure 4A,B) and expression of the glyco-
lytic enzyme hexokinase II, whereas it was down in those with re-
duced glycolysis (Figure 4C). Contrastingly, all of the SSc fibroblasts 
showed an increase in glutaminase expression (Figure 4C), suggest-
ing that unlike glycolytic changes, altered glutamine metabolism may 
be a ubiquitous trait in SSc. There was found two SSc patient sam-
ples elevated HK2 (Figure 4C). qRT-PCR analysis showed that, the 
rate-limiting enzyme HK2 and the glucose transporter GLUT1 were 
significantly elevated in SSc fibroblasts compared with healthy con-
trols cells, but that PFK3 was not up-regulated (Table 1).
3.5 | TGF-β1 up-regulates glutaminase-1 via TGF-β 
receptor/Smad
Given that the glutaminase inhibitor G968 potently reduced TGF-
β1 induction of collagen, we sought to identify if TGF-β-1 could 
lead to induction of the enzyme that mediates glutaminolysis, 
GLS1, in stimulated fibroblasts. Figure 5 shows that incubation 
of normal healthy fibroblast with TGF-β1 led to a significant up-
regulation of GLS1 mRNA and that this could be reduced, at least 
partially, through Smad inhibition (5.5 fold change TGF-β1 and ve-
hicle vs 2.25 TGF-β1 and SB431542 P = .003; n = 4). Also, cells 
treated with Smad inhibitor also reduced collagen at the mRNA 
level P = .0113 Student's t test (Figure 5B) Vehicle treated fibro-
blast 1 vs SB431542 0.66 (0.01; 0.13 SD). To probe for other path-
ways outside of Smad, we used the FGFR3 inhibitor PD173074 to 
inhibit this receptor incubation of dermal fibroblast with PD173074 
(20 nmol/L) suppressed TGF-β1-mediated increase in GLS1 expres-
sion, indicating that FGFR3 is partly mediating this effect P = .004 
n = 4 (Figure 5C).
3.6 | TGF-β1 leads to enhanced levels of succinate
Because of the production of α-ketoglutarate after glutaminolysis, 
which can be enhanced by the pro-fibrotic stimulus TGF-β1, we 
postulated that the next product of the tricarboxycylic acid (TCA) 
cycle succinate would be elevated after TGF-β1 stimulation. To this 
end, we stimulated isolated NHDFs with TGF-β1 and found elevated 
levels of succinate 5.8 nmol SD 0.28 v 9.7 nmol SD 0.95, P = .0002 
Student's t test n = 4 (Figure 6A).
Furthermore, we found elevated levels of the succinate recep-
tor GPR91 in SSc dermal fibroblasts P = .0096 n = 4 (Figure 6B). 
Furthermore, treatment of healthy dermal fibroblasts with extra-
cellular succinate (5 mmol/L) led to a significant increased col-
lagen1A1 gene expression (Figure 6C) (1 vs 2.1 fold SD = 0.32; 
P = .0005 Student's t test; n = 4) and collagen release. Using a 
F I G U R E  2   NAD+ levels regulate glycolysis and fibrotic expression in TGF-β1 NHDFs. A, NAD+ levels were measured for NHDFs treated 
with/without 10 ng/mL TGF-β1 using a commercial kit and normalized to protein levels. Statistical significance was tested for using a 
Student's t test and is highly significant. B, The glycolytic parameters of NHDFs treated with/without 10 ng/mL TGF-β1 and or 10 nmol/L 
FK866 were measured on a Seahorse XFp Analyser by performing a glycolysis stress test. Statistical analysis was performed using 1-way 
ANOVA and significant differences between the treatments tested using a Bonferroni post hoc test. C, Expression of collagen I and α-tubulin 
was measured by Western blotting for NHDFs treated with/without 10 ng/mL TGF-β1 and or 10 nmol/L FK866. *Represents P < .05, 
**P < .01, ***P < .0001. Error bars represent the mean (n = 5 for the NAD+ assay and n = 3 for the glycolysis stress test) ±SEM
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luciferase reporter for the Smad-binding element, we could see no 
increase in luciferase activity after succinate incubation (Figure 6D, 
no significant difference control versus succinate treated Student's 
t test P=>.05; n = 3), indicating no TGF-β activation. Because suc-
cinate in other systems has been found to activate the MAPK p38, 
we examined the phosphorylation status of p38 after stimula-
tion with succinate (5 mmol/L) in normal healthy fibroblasts after 
15 minutes. Figure 6E demonstrates the phosphorylation of p38 
after 15 minutes by Western blot showing weak phosphorylation 
only (Figure 6E).
3.7 | The metabolic modulator Itaconate 
reduces collagen
Itaconate is metabolic by-product of the TCA cycle. It is generated by 
the gene Immune-responsive gene 1 (IRG1) by decarboxylating cis-
aconitate.24 This is one of the most highly up-regulated molecules 
after inflammation is induced and inhibits oxidation of succinate and 
is potently anti-inflammatory.25 The purpose of up-regulation of ita-
conate appears to be to restrain inflammation and its subsequent 
consequences. Recently, a cell permeable derivative of itaconate 
termed 4-octyl itaconate was derived and found to be both cell per-
meable and anti-inflammatory by up-regulating nrf-2 and subsequent 
antioxidant genes.21 Thus, we used 4-octyl itaconate in dermal fibro-
blast from three SSc donors. Figure 7A demonstrates that incuba-
tion with the cell permeable derivative of itaconate leads to reduced 
collagen in these cells compared with vehicle control. Nrf-2 appears 
to be up-regulated by itaconate in immune cells.21 Nrf-2 is a potent 
master regulator of cellular stress response and sets in motion after 
up-regulation a set of specific genes involved glutathione synthe-
sis and antioxidant genes; one of which is Haem Oxygenase-1 (HO-
1).26 HO-1 gene expression is significantly elevated after itaconate 
treatment; vehicle mean fold change 1 (0.01) vs 5.86 (1.1) Figure 7B 
(P = .0014 Student's t test; n = 3). HO-1 is a direct transcriptional tar-
get of the master antioxidant regulator nrf-2 and therefore a proxy 
of nrf-2 engagement.26
4  | DISCUSSION
SSc and indeed other fibrotic conditions are characterized by 
excessive myofibroblast proliferation and the exuberant produc-
tion of ECM.27 Resembling a milder version of the ‘Warburg ef-
fect’ observed in cancer,28 we show that the pro-fibrotic stimulus 
TGF-β1 up-regulates glycolysis, with the concomitant inhibition 
of glycolysis preventing development of the fibrotic phenotype. 
We also find that succinate is elevated and that succinate itself 
F I G U R E  3   Glutaminase activity is essential for TGF-β1 driven effects. A, NHDFs were treated with/without 10 ng/mL TGF-β1 and 
various concentrations of L-glutamine. Proteins of interest were quantified by Western blotting. B, The expression of Collagen I and 
α-tubulin was quantified by Western blotting for NHDFs treated with/without 10 ng/mL TGF-β1 and/or the specific glutaminase inhibitor 
G968 (10 µmol/L). C, The glutaminase inhibitor did not change the expression of collagen1A1 gene expression. Cells were treated with or 
without the glutaminase inhibitor G968 (10 µmol/L) for 36 h after which qRT-PCR was performed for collagen1A1 gene expression P = .13 
Student's t test n = 3. Data are the mean and SD and is normalized to 18S as the housekeeping gene (n = 3)
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up-regulates collagen. We posit that the importance of glycoly-
sis for TGF-β1 driven fibrosis is in part due to the production of 
key biosynthetic intermediates for ECM synthesis and fibrosis. 
We also demonstrate that the importance metabolite itaconate 
reduces collagen in SSc fibroblasts.
However, in addition to glycolysis, the conversion of glutamine 
to glutamate is essential for the production of the key collagen 
I precursor α-ketoglutarate and building blocks for non-essential 
amino acid synthesis, suggesting glutamine metabolism is also in-
tegral for the development of fibrosis.29 This is evidenced by the 
ability of the specific glutaminase inhibitor G968 to attenuate col-
lagen I expression in TGF-β1 1 treated NHDFs. Interestingly, it did 
not reduce collagen at the transcript levels, suggesting a post-tran-
scriptional effect. Indeed, in liver fibrosis induced in animal mod-
els with carbon tetrachloride pre-treatment with a glutaminase 
inhibitor potently reduced liver fibrosis.30 Indeed, liver fibrosis 
myofibroblasts, hepatic stellate cells, were highly dependent on 
glutaminolysis for their conversion and metabolic needs and inhi-
bition with the compound we used, G968, potently reduced their 
fibrotic phenotype.30
Glutaminolysis has also been found to be critically important in 
mediating fibrosis in idiopathic lung fibroblasts 31 as siRNA-mediated 
reduction of glutaminase 1 resulted in suppression of the production 
of collagen and other important ECM proteins.31 The mechanism in 
regard to the up-regulation of anti-apoptotic proteins associated with 
the pulmonary fibroblast phenotype involves histone trimethylation 
H3K27me3, which epigenetically regulates the target protein. Given 
that epigenetic regulation is also a key event in SSc27,32 and in partic-
ular trimethylation has been shown to be important,33 we speculate 
that histone modification after production of α-ketoglutarate may be 
critically important in ECM deposition. ROS has also been found to 
play a role in SSc34 and could also influence metabolism.
It was of note that there was significant variation in the levels 
of glycolysis, glycolytic capacity and glycolytic reserve between the 
SSc fibroblasts from different donors suggesting that the involve-
ment of glycolysis may be highly variable between different patients 
and heavily influenced by a number of other factors. However, in 
line with its predicted role as a pro-fibrotic pathway, glycolysis was 
elevated in the fibroblasts showing the highest collagen expression, 
although this is a very tentative correlation given the low sample 
size. This fits with the discovery that lactate was substantially ele-
vated in SSc dermal blister fluids,35 which is in close contact to the 
underlying fibroblasts.
F I G U R E  4   Glycolysis and glutaminase expression in SSc patient derived dermal fibroblasts. Glycolytic parameters for dermal fibroblasts 
from healthy controls (n = 3) and SSc patients (n = 4) were measured using a glycolysis stress test, displayed individually (A) and as disease 
and control averages (B). Statistical analysis was performed using 1-way ANOVA. C, Expression of glutaminase (KGA/GAC), hexokinase II, 
collagen I and α-tubulin in SSc and healthy control fibroblasts was analysed by Western blotting. Error bars represent the mean (n = 3) ±SEM
TA B L E  1   Gene expression of glycolytic genes in healthy control 
and SSc fibroblasts
Gene
Fold change SSc versus 
control (SD)
Significant 
(Student's t test)
HK2 2.7 (0.37) Yes P = .0001
GLUT1 3.4 (1.44) Yes P = .01
PFK3 1.14 (0.22) No P = .26
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Unlike glycolysis, glutaminase 1 expression was elevated in all 
SSc fibroblasts, hinting that this may be a defining feature of the dis-
ease. Given TGF-β1 increases glycolysis and is known to be elevated 
in SSc, it may be that the combination of TGF-β1-enhanced glycolysis 
and endogenous up-regulation of glutamine metabolism is key to the 
development of fibrotic skin lesions in SSc.
We further show that TGF-β1 leads to up-regulation of the 
key enzyme that mediate glutaminolysis in normal dermal fibro-
blasts and that this is mediated, at least partly, through Smad 
activation. The cellular use of glutamine begins with the enzyme 
glutaminase that initiates glutaminolysis to generate glutamate 
and subsequently α-ketoglutarate via glutamine dehydroge-
nases.36 Although the induction of glutaminase 1 could also be 
partially mediated through non-canonical TGF-β signalling path-
ways. To examine the role of Smad-independent pathways after 
TGF-β1 stimulation of glutaminase 1, we inhibited the FGFR3 and 
demonstrated that this inhibition also attenuated glutaminase 1 
induction. Of note, it was recently described that FGFR3 inhi-
bition reduced lung fibrosis markers in isolated lung fibroblasts 
mediated by TGF-β and in the bleomycin lung fibrosis model 
FGFR3 inhibitors reduced fibrosis in vivo37 and its ligand FGF9 
is found in hepatic stellate cells of the fibrotic liver.38 In a recent 
manuscript, it was demonstrated that in lung fibroblasts TGF-β1 
leads to up-regulation of glutaminase 1 in these cells via Smad-
dependant pathways and non-canonical pathways.39 Indeed, it 
was demonstrated that siRNA-mediated reduction in Smad3 re-
versed the up-regulation of glutaminase 1 and that the effect 
was also mediated by down-regulation of the NAD + deacetyl-
ase Sirtuin 7 (SIRT7) leading to elevated acetylation of FOXO1 
that is then able to directly bind the promoter of glutaminase 
139—as acetylation is more permissive to transcription. Although 
we did not look at the levels of SIRT7 after TGF-β1 stimulation 
it could be that as in the lung,39 this leads to reduced deacetyl-
ation of FOXO1 and binding of the promoter. It is interesting to 
note, however, that SIRT7 has been found to be significantly de-
creased in the skin and lungs of SSc patients40 and that enforced 
overexpression of SIRT7 through a SIRT7-GFP plasmid reduced 
collagen and α-smooth muscle actin levels.40 Although this re-
quires further experimentation, this could be the underlying 
mechanism in the increase in glutaminase 1.
F I G U R E  5   TGF-β1 up-regulates Gls1 in dermal fibroblasts via Smad. A, Expression of Gls1 was measured by qRT-PCR after stimulation 
with TGF-β1 and pre-treated with the Smad inhibitor SB431542 (1 µmol/L) or vehicle control. Data are the mean and standard deviation 
*= Significant Two-way ANOVA; n = 4 donors. B, Collagen1A1 gene expression was quantified after vehicle control or SB431542 and after 
48 h with TGF-β1 incubation. Data were normalized to the housekeeping gene 18S and shown as fold change compared with vehicle control 
treated cells. Data are the mean and SD *= significant Student's t test P = .0113; n = 3 donors. C, Expression of Gls1 was measured by qRT-
PCR after stimulation with TGF-β1 and pre-treated with the FGFR3 inhibitor PD173074 (20 nmol/L) or DMSO vehicle control treated. Data 
are the mean and standard deviation. *=Significant Two-way ANOVOA; n = 4
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Furthermore, we show that stimulation of NHDFs with TGF-
β1 leads to elevated succinate levels. Succinate is a metabolite of 
the TCA cycle that has recently been identified as not merely a 
by-product but an active metabolite, in some cases acting as a dan-
ger signal.41,42 Indeed, succinate has been found to enhance immu-
nity and signal through a G protein-coupled receptor (GPR91)43 and 
F I G U R E  6   TGF-β1 up-regulates succinate levels. A, Healthy dermal fibroblasts were stimulated with TGF-β1 or not, and after 36 h 
succinate was quantified colorimetrically * significantly different compared with controls P = .0002; Student's t test. Data are the mean and 
SD n = 4. B, GPR91 expression is higher in SSc dermal fibroblasts *Significantly different compared with healthy controls P = .0096 n = 4 
donors. C, Collagen1A1 was quantified after succinate incubation (5 mmol/L) using qRT-PCR, Data are normalized to the housekeeping 
gene 18S and shown as fold change compared with control. Data are mean and SD * significant difference compared with control P = .0005 
Student's t test; n = 4. D, No significant difference in SMAD activation after succinate incubation. Luciferase activity is determined after 
stimulation with succinate. Data are normalized to untreated control set to 100% luciferase set to Renilla luciferase for transfection efficacy 
n = 3. E, Western blot of healthy dermal fibroblast incubated with succinate after 15 min and the cells were probed with phosphorylated 
p38 and re probed with β-actin for equal loading. C = control untreated S = Succinate 5 mmol/L
F I G U R E  7   The metabolic regulator Itaconate reduces collagen in SSc fibroblasts. A, Western blot to quantify collagen 1 in SSc dermal 
fibroblasts exposed to the cell permeable 4-octyl Itaconate (100 µmol/L) or vehicle control for 48 h. Cells were lysed and subjected to PAGE 
and transferred and probed with collagen 1 antibody. Β-actin is used to confirm equal loading of protein. B, Elevated HO-1 gene expression 
after Itaconate stimulation (100 µmol/L). Data are the mean from three individual donors each point a donor. Data are normalized to the 
housekeeping gene 18S (*P = .0014 Student's t test; n = 3)
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exacerbates a mouse model of arthritis.44 Mice which are knocked 
out for GPR91 have reduced immune rejection to transplant.43 
Succinate appears to be a danger signal that leads to activation of 
hepatic stellate cells, the myofibroblasts of the liver.45
Furthermore, succinate infusion has been found to cause cardiac 
fibrosis in a GPR91-dependant fashion and stimulates ERK phos-
phorylation.46 Recently, it was demonstrated that succinate was 
associated with fibrosis in inflammatory bowel disease and these pa-
tients have higher levels of GPR91 expression.47 Additionally, mice 
with GPR91 deletion were protected from fibrosis in the intestine 
and GPR91 KO isolated fibroblasts could not up-regulate collagen 
after succinate incubation.47 We found significantly higher levels of 
the succinate receptor GPR91 in SSc cells and addition of extracel-
lular succinate led to elevated collagen expression in dermal fibro-
blasts. This suggests that succinate itself is pro-fibrotic. Of course, 
succinate is made in a variety of cell types and in SSc succinate could 
be released from macrophages to active the fibroblast to undergo 
fibrotic changes leading to enhanced ECM. Given that macrophages 
are key cell types in SSc,48,49 this is a plausible explanation. How 
succinate may up-regulate collagen is unknown but appears to be 
independent of TGF-β1 as the Smad reporter assay did not increase 
after succinate incubation. Others have demonstrated succinate me-
diates its effects through stabilization of Hypoxia Inducible factor 
1-α (HIF-1α).50 It is known that HIF-1α is a pro-fibrotic transcription 
factor. We also saw some weak phosphorylation of p38, as others 
have suggested that succinate can signal through this intermediate. 
Although it is unknown, whether this weak activation of P38 is suf-
ficient for ECM deposition.
We also demonstrate that 4-octyl itaconate—a cell perme-
able form of itaconate reduced collagen1 expression in SSc der-
mal fibroblasts. Itaconate is a by-product of the TCA cycle that is 
hugely up-regulated in inflammation.51 Although associated with 
activated immune cells, itaconate is found in many stromal cell 
compartments also51 indicating it is not restricted to immune cells 
exclusively. Thus, it appears that itaconate is anti-inflammatory 
presumably up-regulated to restrain unwanted and damaging per-
sistent inflammation. The mechanism has recently been shown to 
be through up-regulation of nrf-2, via alkylation of specific residues 
on keap1.21 Keap1 is the negative regulator of nrf-2 by targeting 
this for ubiquitination and subsequent cellular degradation26—
thereby regulating tight control of its activity. Recent studies have 
shown that modifications to keap1 by a derivative of itaconate lead 
F I G U R E  8   Putative pathway of metabolic alterations via TGF-β1 TGF-β1 binds the cognate receptor and then causes downstream 
signalling from the canonical pathway to activate glutaminolysis via up-regulation of glutaminase 1 enzyme, and this leads to fibrosis 
possibly through increased epigenetic marks. Glycolysis is also up-regulated leading to fibrosis via up-regulation of glycolytic enzymes. 
Both pathways can be blocked with G968 (glutaminase 1 inhibitor) or 2-DG and 3PO for glycolysis. Extracellular succinate also up-regulates 
fibrosis possibly through the activation of P38 via phosphorylation of this intracellular signalling molecule. 4-OI mediates an anti-fibrotic 
effect by first being cleaved to itaconate via esterases and alkylates cysteine residue 161 (Cys 161) of KEAP1 thus repressing its ability 
to modify nrf-2 to be degraded via the proteosome. Nrf-2 is then up-regulated and downstream targets such as HO-1 are increased that 
are anti-fibrotic. 2-DG; 2Deoxyglucose, 4-OI; 4-octyl itaconate, HO-1; Haem oxygenase-1, nrf2; nuclear factor erythroid-2-related factor, 
TGF-β1; transforming growth factor beta 1
12  |     HENDERSON Et al.
to enhancement of nrf2 and downstream reduced inflammation, in 
a model of skin inflammation-driven by IL-17—itaconate reduced 
this skin pathology25 significantly. We show here that itaconate 
reduced collagen significantly and that the bona fide target gene 
of nrf-2, HO-1 is significantly up-regulated in these cells. In a re-
cent study, itaconate and its derivative were shown to reduce liver 
damage and fibrosis in a ischaemia reperfusion model of liver in-
jury.52 Furthermore, it was recently shown that itaconate reduces 
inflammation through inhibition of glycolysis metabolism via co-
valent modification of GAPDH.53 Interestingly, mice in whom nrf2 
is reduced are less protected from the effects of itaconate—we 
suggest that itaconate is anti-fibrotic and is dependent upon nrf2 
for this action. Interestingly, a previous study has demonstrated 
significantly reduced nrf2 expression in skin and lung tissues from 
SSc patients and nrf2 knockout mice has much exaggerated skin 
fibrosis in the bleomycin mouse model.54 Furthermore, incubation 
of cells with interferon-β significantly enhanced the concentra-
tion of intracellular itaconate,21 which may explain the reduction 
of collagen and alpha-smooth muscle actin in SSc fibroblasts by 
interferon-β.55
Metabolism and metabolic reprogramming have recently seen a 
renaissance in research, and its importance is now being appreciated 
in many diseases.56 Importantly, this introduces the possibility of ap-
plying metabolically targeted interventions such as 3PO and G968 
for the treatment of SSc. Furthermore, the novel observation of suc-
cinate dysregulation in SSc warrants further investigation. Finally, 
we show that the important metabolic product itaconate can reduce 
collagen in SSc fibroblasts. Figure 8 illustrates a putative pathway 
where inhibition can occur and the use of itaconate and its possible 
mechanism. Given that itaconate has now been shown to inhibit the 
inflammasome and reduce severity in an animal model of peritoni-
tis57 and liver fibrosis,52 it may be considered in skin fibrosis.
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